Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers.
COVID pandemic
Chemotherapy
Coronavirus
Oncological patients
Prevalence
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
08
09
2020
accepted:
30
12
2020
pubmed:
28
1
2021
medline:
28
4
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
It has been assumed that cancer patients, especially those undergoing chemotherapy, are at increased risk for infection and severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the general population. After the first alert message from the local healthcare service, a series of drastic measures were taken at our outpatient clinic to contain the spread of coronavirus disease 2019 (COVID-19). In this retrospective study, all consecutive cancer outpatients completed a baseline SARS-CoV‑2 test via real-time polymerase chain reaction (RT-PCR) from 15 March to 26 May 2020. In the later phase, after the peak of the pandemic, patients as well as healthcare workers were tested for anti-SARS-CoV‑2 IgG antibodies. Between 15 March and 26 May 2020, 0.78% (N = 5/640) cancer patients tested positive for SARS-CoV‑2 by RT-PCR. Between 22 June and 17 July 2020, anti-SARS-CoV‑2 IgG antibodies were detected in 2 out of 250 (0.8%) cancer patients and 2 out of 36 (5.5%) healthcare workers. In only 1 out of 4 cancer patients with confirmed COVID-19 infection, could SARS-CoV‑2 antibodies be detected. Our findings suggest that the majority of our patients and healthcare workers had not been infected with SARS-CoV‑2 and rapidly implemented measures were effective. Maintenance of preventive measures should be continued until vaccines or specific treatments are available.
Sections du résumé
BACKGROUND
BACKGROUND
It has been assumed that cancer patients, especially those undergoing chemotherapy, are at increased risk for infection and severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the general population. After the first alert message from the local healthcare service, a series of drastic measures were taken at our outpatient clinic to contain the spread of coronavirus disease 2019 (COVID-19).
METHODS
METHODS
In this retrospective study, all consecutive cancer outpatients completed a baseline SARS-CoV‑2 test via real-time polymerase chain reaction (RT-PCR) from 15 March to 26 May 2020. In the later phase, after the peak of the pandemic, patients as well as healthcare workers were tested for anti-SARS-CoV‑2 IgG antibodies.
RESULTS
RESULTS
Between 15 March and 26 May 2020, 0.78% (N = 5/640) cancer patients tested positive for SARS-CoV‑2 by RT-PCR. Between 22 June and 17 July 2020, anti-SARS-CoV‑2 IgG antibodies were detected in 2 out of 250 (0.8%) cancer patients and 2 out of 36 (5.5%) healthcare workers. In only 1 out of 4 cancer patients with confirmed COVID-19 infection, could SARS-CoV‑2 antibodies be detected.
CONCLUSION
CONCLUSIONS
Our findings suggest that the majority of our patients and healthcare workers had not been infected with SARS-CoV‑2 and rapidly implemented measures were effective. Maintenance of preventive measures should be continued until vaccines or specific treatments are available.
Identifiants
pubmed: 33502609
doi: 10.1007/s00508-020-01807-6
pii: 10.1007/s00508-020-01807-6
pmc: PMC7838655
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-363Références
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
doi: 10.1056/NEJMoa2002032
Hartley DM, Perencevich EN. Public health interventions for COVID-19: emerging evidence and implications for an evolving public health crisis. JAMA. 2020; https://doi.org/10.1001/jama.2020.5910 .
doi: 10.1001/jama.2020.5910
pubmed: 32745200
pmcid: 7391181
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV‑2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
doi: 10.1016/S1470-2045(20)30096-6
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-coV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91.
pubmed: 32345594
pmcid: 32345594
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; https://doi.org/10.1001/jama.2020.4683 .
doi: 10.1001/jama.2020.4683
pubmed: 32203977
Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV‑2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108–10.
doi: 10.1001/jamaoncol.2020.0980
Peng L, Zagorac S, Stebbing J. Managing patients with cancer in the COVID-19 era. Eur J Cancer. 2020;132:5–7.
doi: 10.1016/j.ejca.2020.03.028
ESMO. Cancer patient management during COVID-19 pandemic. 2020. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic . Accessed 27 July 2020.
NICE. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020. https://www.nice.org.uk/guidance/ng161 . Accessed 28 July 2020.
Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys. 2020;107(4):618–27.
doi: 10.1016/j.ijrobp.2020.04.016
World of Meters. Italy. 2020. https://www.worldometers.info/coronavirus/country/italy/ . Accessed 28 July 2020.
Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV‑2 in 10 sites in the United States, march 23–may 12. JAMA Intern Med. 2020; https://doi.org/10.1001/jamainternmed.2020.4130 .
doi: 10.1001/jamainternmed.2020.4130
pubmed: 32692365
pmcid: 7686880
Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV‑2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020; https://doi.org/10.1016/S0140-6736(20)31304-0 .
doi: 10.1016/S0140-6736(20)31304-0
pubmed: 32534626
pmcid: 7289564
Fong D, Rauch S, Petter C, et al. Infection rate and clinical management of cancer patients during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy. ESMO Open. 2020;5(3):e810.
doi: 10.1136/esmoopen-2020-000810
Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the Abbott architect SARS-coV‑2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020; https://doi.org/10.1128/JCM.00941-20 .
doi: 10.1128/JCM.00941-20
pubmed: 33028602
pmcid: 7383515
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.
doi: 10.1001/jama.2020.1585
Palmieri L, Andrianou X, Barbariol P, et al. Characteristics of SARS-CoV‑2 patients dying in Italy. 2020. https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths . Accessed 28 July 2020.
Omarini C, Maur M, Luppi G, et al. Cancer treatment during the coronavirus disease 2019 pandemic: do not postpone, do it! Eur J Cancer. 2020;133:29–32.
doi: 10.1016/j.ejca.2020.04.034
Tao L, Guang Z, Huangheng T, et al. Low prevalence of IgG antibodies to SARS-CoV‑2 in cancer patients with COVID-19. Int J Cancer. 2020; https://doi.org/10.1002/ijc.33148 .
doi: 10.1002/ijc.33148
pubmed: 33091960
pmcid: 7300852
Woo MS, Steins D, Häußler V, et al. Control of SARS-CoV‑2 infection in rituximab-treated neuroimmunological patients. J Neurol. 2020; https://doi.org/10.1007/s00415-020-10046-8 .
doi: 10.1007/s00415-020-10046-8
pubmed: 32654064
pmcid: 7353821
Meca-Lallana V, Aguirre C, del Río B, et al. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020; https://doi.org/10.1016/j.msard.2020.102306 .
doi: 10.1016/j.msard.2020.102306
pubmed: 32593958
pmcid: 7831671
Fallet B, Kyburz D, Walker UA. Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment. Arthritis Rheumatol. 2020; https://doi.org/10.1002/art.41380 .
doi: 10.1002/art.41380
pubmed: 32458534
pmcid: 7283641
Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV‑2 in China. Nat Med. 2020; https://doi.org/10.1038/s41591-020-0949-6 .
doi: 10.1038/s41591-020-0949-6
pubmed: 33046868
pmcid: 7992505
Lahner E, Dilaghi E, Prestigiacomo C, et al. Prevalence of Sars-Cov‑2 infection in health workers (HWs) and diagnostic test performance: the experience of a teaching hospital in central Italy. Int J Environ Res Public Health. 2020;17(12):4417.
doi: 10.3390/ijerph17124417